EYE-GO A/S

Company's own description on virk.dk

EYE-GO develops disruptive eye care technology that improves the quality of life of people around the world suffering from severe and chronic eye conditions. Revolutionizing the exiting eye drop bottle market, the MistGo® product is a novel ocular drug delivery system that is the first viable and truly replacement of the eye drop bottle.MistGo® works by micro-dosing a thin mist into the eye and is part of the next generation delivery systems capable of administering micro-doses for preservative-free liquids. MistGo® is the only system effectively removing all the well-known negative effects and barriers from eye-drop bottles. Patients receive the optimal dose with precise installation every time, minimizing systemic exposure. The product has an eye guide which ensures accurate delivery of the medication into the eye and at the same time reduces risk of contamination by ensuring that no parts of the product touch the ocular surface. The technology behind transforms the 6-8 µL into a precisely targeted mist and is patented in the USA, Europe, Japan, and pending patents in China.In 2025 we have fine-tuned the MistGo® product and customers have made trials with specific real-life formulations. These tests have confirmed that MistGo® has a wide performance window regarding viscosity, and the system does not clog even with sticky formulations.In 2025 we received a convertible loan from a strategic investor (Topcon Healthcare Inc.), which is an international world-leading ophthalmology healthcare company. Topcon wanted us to develop a digitized version of MistGo®, and associated app and back-end system, and this fitted very well with our development strategy. The CEO of Topcon Healthcare Inc. and a world leading glaucoma doctor (KOL) has joined the board of EYE-GO A/S.The digitized version will record if the patient is using MistGo® correctly and it transfers data of the use of MistGo® in real time to a database. This makes it possible for doctors to monitor if their patients are taking the medication as prescribed, and the doctors can monitor if their patients are following the treatment program. The digitized version is also a great help for CRO’s in clinical trials, as they can follow the progress of their clinical trials in real time and adjust if necessary. Also, Pharmaceutical companies can better measure the real effect of their medicine with the digitized MistGo®.Our business model is to license to pharma companies against milestone payments and generate recurring revenue from long-term supply agreements. EYE-GO targets pharma companies with prescription (Rx) medicine for treatment of chronic eye diseases. The primary segments are glaucoma (a $3.2B US market) and dry eye disease (“DED”, a $1.5B US market). Secondary segments are presbyopia (with expected double digit $B revenue within 5-10 years) and myopia. MistGo® is for young companies (new innovative delivery system for new innovative drugs) as well as established companies (life-cycle extension of current drugs).